Galderma Laboratories, has received United States Food and Drug Administration approval for its Epiduo (adapalene and benzoyl peroxide) Gel 0.1% / 2.5% pump dispenser. The once-daily, topical acne treatment is indicated for the topical treatment of acne vulgaris in patients 12 years and older. It combines two well-established active ingredients: adapalene, a retinoid; and benzoyl peroxide, a well-known antimicrobial. The Epiduo Gel pump will be available via prescription in the first quarter of 2012.
“Because acne is caused by a multitude of factors, management of the condition has traditionally relied on combination therapy,” said Linda Stein Gold, MD, director of dermatology clinical research and division head of dermatology at Henry Ford Health System in Detroit. “I often prescribe Epiduo Gel, which combines two effective medications into one product to treat both inflammatory and non-inflammatory lesions topically. My patients have often achieved very positive results, and I believe that patients will be excited about the new pump delivery system.”
